A review of serious adverse events linked with GLP-1 agonists in type 2 diabetes mellitus and obesity treatment
The DOI matches its Crossref record; 56 of the 58 references it cites were found in a registry or an index.
Abstract
Review of serious adverse events linked with GLP-1 agonists in T2D and obesity treatment. Evidence remains mixed on risks of pancreatitis, thyroid cancer, and other serious AEs.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A non-systematic review by Tobaiqy et al., 2024 [128] did not allow the authors to draw any firm conclusions, given the mixed results of the included trials.”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [128]
In the citing paper
“A number of reviews on similar topics have also been previously published [124-128], focusing on efficacy [125] or case reports [126], being narrative reviews [127,128], or including a much smaller sample of studies [124].”
From Symptomatic Adverse Events and Quality of Life Related to Incretin-Based Medicines for Obesity: A Systematic Review Involving >400,000 Subjects (2025) · cites this paper as [128]
Citations
Cites
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 6×
“[ 3].”
InfluentialTirzepatide Once Weekly for the Treatment of Obesity
Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206038 · Cited by 3,838
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
Lincoff, A. M., Brown-Frandsen, K., Colhoun, H. M., Deanfield, J., Emerson, S. S., Esbjerg, S., Hardt-Lindberg, S., Hovingh, G. K., Kahn, S. E., Kushner, R. F., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2307563 · Cited by 3,236
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Adverse drug reactions: definitions, diagnosis, and management
Edwards, I. R., & Aronson, J. K. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02799-9 · Cited by 2,979
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes
Holman, R. R., Bethel, M. A., Mentz, R. J., Thompson, V. P., Lokhnygina, Y., Buse, J. B., Chan, J. C., Choi, J., Gustavson, S. M., Iqbal, N., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1612917 · Cited by 2,162
Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
Kosiborod, M. N., Abildstrøm, S. Z., Borlaug, B. A., Butler, J., Rasmussen, S., Davies, M., Hovingh, G. K., Kitzman, D. W., Lindegaard, M. L., Møller, D. V., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2306963 · Cited by 1,669 · cited 1×
“In contrast, others find no signifi - cant association [ 9, 10].”
Sattar, N., Lee, M. M. Y., Kristensen, S. L., Branch, K. R. H., Del Prato, S., Khurmi, N. S., Lam, C. S. P., Lopes, R. D., McMurray, J. J. V., Pratley, R. E., et al. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00203-5 · Cited by 1,599 · cited 1×
“…patients with heart failure with preserved ejection fraction (HFpEF) and obe - sity treated with semaglutide (2.4 mg) experienced more significant reductions in symptoms and physical limita - tions, improved exercise function, and more significant weight loss than those receiving a placebo [ 30 ].”
InfluentialPancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies
Elashoff, M., Matveyenko, A. V., Gier, B., Elashoff, R., & Butler, P. C. (2011) · Gastroenterology · doi:10.1053/j.gastro.2011.02.018 · Cited by 944 · cited 1×
“Patients are advised against discontinuing GLP agonists without medical consultation, and healthcare professionals should monitor for mood changes [ 45].”
Cited by
Xie, X., Yang, S., Deng, S., Liu, Y., Xu, Z., & He, B. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1613610 · Cited by 57
“These effects are closely related to the activation of GLP-1 receptors in both central and peripheral pathways, often leading to reduced treatment adherence or even discontinuation, which can compromise therapeutic outcomes (Tobaiqy, 2024).”
Georgianos, P. I., Vaios, V., Koufakis, T., & Liakopoulos, V. (2024) · Drugs · doi:10.1007/s40265-024-02091-8 · Cited by 27
“Other commonly reported side effects are hypoglycemia (mainly in patients receiving combination therapy with insulin), tachycardia, gallbladder disease, pancreatitis, and retinopathy [41].”
Tian, Q., Song, Y., Deng, Y., & Lin, S. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1593134 · Cited by 26
“These fi ndings are consistent with reports on other GLP-1 receptor agonists, including semaglutide and liraglutide, which also demonstrate a high prevalence of nausea and vomiting as common treatment-related side effects (40, 41).”
Scheen, A. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16453 · Cited by 25
Zhao, X., Liu, Y., Wang, D., Li, T., Xu, Z., Li, Z., Bai, X., & Wang, Y.-C. (2025) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2025.5515 · Cited by 12
“…with GLP‑1RAs, among which gastrointestinal diseases (commonly nausea, diarrhea, vomiting and constipation) are the most frequently reported; however, most gastrointestinal events are of mild to moderate severity, transient and do not require permanent discontinuation of treatment (179,180).”
Fu, X., Jing, Y., Yang, R., et al. (2025) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2025.119746 · Cited by 10
Mechanistic underpinnings of AGEs-RAGE via DIAPH1 in ischemic, diabetic, and failing hearts
Yepuri, G., Hasan, S. N., Kumar, V. S., Manigrasso, M. B., Theophall, G. G., Shekhtman, A. G., Schmidt, A. M., & Ramasamy, R. (2025) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00685.2024 · Cited by 9
GLP-1 receptor agonists in diabetes and weight loss: the double-edged sword of innovation and risks
Ilias, Ι., Zabulienė, L., & Rizzo, M. (2025) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2024.1530811 · Cited by 13
DNA‐mediated UCP1 overexpression in adipose tissue: A promising anti‐obesity gene therapy
Zhao, Z., Hu, L., Song, B., Wu, Q., Lin, J., Liu, Q., Liu, S., Li, J., Wang, M., Li, J., et al. (2025) · Clinical and Translational Medicine · doi:10.1002/ctm2.70491 · Cited by 9
Kushner, R. F., Johansen, O. E., Araujo Torres, K., Phan, T.-M., & Marczewska, A. (2025) · Obesities · doi:10.3390/obesities5020029 · Cited by 5
“A non-systematic review by Tobaiqy et al., 2024 [128] did not allow the authors to draw any firm conclusions, given the mixed results of the included trials.”
Tavares, A. C. M., Martins, M. Y. M., de Souza, G. F., Lima, E. M., Rocha, C. A., de Souza, L. C., Simões, J. M. L., ARAÚJO, N. O. D., & Cavalcante, M. B. (2025) · Journal of Reproductive Immunology · doi:10.1016/j.jri.2025.104538 · Cited by 12
Florescu, A. G., Pucerea, S. A., Floria, M., Rusu, E., Cuiban, E., Jinga, M., Galrinho, R. D., & Stanciu, S. M. (2025) · Romanian Journal of Military Medicine · doi:10.55453/rjmm.2025.128.6.9 · Cited by 8
“Generally, gastrointestinal adverse effects are the most common and the most frequent cause of drug discontinuation [35].”
ALSaleh, N., Alshamat, R. A., Almrzouqi, W. T., Alhebshi, M., Aljuhani, T., Almahdi, R., Almaghrabi, M. M., Rammal, A. A., Ageel, A. H., & Alzahrani, M. A. (2026) · Journal of Gastrointestinal Cancer · doi:10.1007/s12029-025-01377-8 · Cited by 4
“Glucagon-like peptide-1 receptor agonists (GLP-1 RA) like samaglutide and Terzipatide, are widely utilized for the treatment of type 2 diabetes mellitus and obesity due to its proven efficacy in glucose regulation, weight loss, and car - diovascular protection [ 1, 2 ].”
Blum, K., Dennen, C. A., Lewandrowski, K.-U., Sharafshah, A., Pinhasov, A., Bowirrat, A., Elman, I., Cadet, J. L., Braverman, E. R., Thanos, P. K., et al. (2025) · Medical Hypotheses · doi:10.1016/j.mehy.2025.111612 · Cited by 4
Adverse effects and other aspects of drugs with incretin effect
Ballesteros-Pomar, M. D., & Lesmes, I. B. (2025) · Medicina Clínica (English Edition) · doi:10.1016/j.medcli.2025.107041 · Cited by 4
Zhao, W., Niu, X., Zhou, X., Shi, R., & Zhou, X. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33885-4.00007-x · Cited by 1
Prokop, R. L., Stork, B. F., & James, L. C. (2025) · Military Medicine · doi:10.1093/milmed/usaf321 · Cited by 4
Kozhukhov, N. D., Karpova, A. R., Sadretdinova, A. A., Kodoeva, D. G., Kardanova, A. S., Прошина, А. С., Avbakirova, A. S., Kilichev, D. R., Metov, I. S., Magomedov, L. M., et al. (2025) · Obstetrics Gynecology and Reproduction · doi:10.17749/2313-7347/ob.gyn.rep.2025.657 · Cited by 1
Chu, C., Ghahramani, D., Giannakeas, V., Jeyaparan, J., Bhattacharyya, O. K., Gomes, T., Ivers, N. M., & Tadrous, M. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.12.009
Eco‐Nutrition and Systems‐Based Practice: A Narrative Review
Gallegos, D. (2026) · Journal of Human Nutrition and Dietetics · doi:10.1111/jhn.70276 · Cited by 1
Basso, A. L. F., Falcetti, E. M., Coelho, R. P., Maia, G. A., de Oliveira, L. R. B., Prates, F. F., & TREPICHE, S. D. (2026) · Research Society and Development · doi:10.33448/rsd-v15i6.51184
Kalagi, F., Hamed, L., Alrubaian, S. S., Almuzain, F. A., Alturkestany, N., Bah, S., & AlGindan, Y. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1902763
Yang, N., & Jin, J. (2026) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2026.03.005
Zhong, X., Zhao, Y., Han, M., Zheng, Q., Cheng, Q., Shi, B., & Zhang, Y. (2026) · Hormone and Metabolic Research · doi:10.1055/a-2923-3830
Metadata
- Authors
- Tobaiqy, M.
- Affiliations
- University of Jeddah (SA)
- Corresponding author
- Tobaiqy, Mansour
- ORCID
- Tobaiqy, Mansour
- Venue
- Pharmacological Reports
- Published
- 2024-08-02
- Volume
- 76
- Issue
- 5
- Pages
- 981-990
- ISSN
- 1734-1140 (ISSN-L)
- 2299-5684
- OpenAlex
- W4401252114
- Semantic Scholar
- e8ec052a486a6c62e54e2ef0c69912aff2356f33
- Cited by
- 25
- References
- 58
- Citations by year
- 2026: 6 · 2025: 18 · 2024: 1
- FWCI
- 1.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmacological Reports (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Keywords
- GLP-1 receptor agonists, serious adverse events, drug safety, type 2 diabetes, obesity treatment, anaphylaxis, cardiovascular adverse events, gastrointestinal adverse effects, psychiatric adverse events
- MeSH terms
- Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Obesity
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.